BioMarin closes Alesta Therapeutics acquisition
BioMarin (BMRN) announced the close of its acquisition of Alesta Therapeutics.
Story updates
01:05:50 PM UTC
SquawkNews
Acquisition adds ALE1, a potential first oral therapy for hypophosphatasia to clinical pipelineSAN RAFAEL, Calif., Sept. 1, 2026 // -- BioMarin Pharmaceutical Inc. (Nasdaq: BMRN) said today that it completed the previously announced agreement to acquire Alesta Therapeutics. The acquisitio…
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.